Found: 20
Select item for more details and to access through your institution.
Treatment of Acute Myeloid Leukemia in the Community Setting.
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. 801, doi. 10.1093/oncolo/oyae051
- By:
- Publication type:
- Article
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
- Published in:
- Oncologist, 2022, v. 27, n. 6, p. 493, doi. 10.1093/oncolo/oyac042
- By:
- Publication type:
- Article
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 2, p. 149, doi. 10.1093/oncolo/oyab040
- By:
- Publication type:
- Article
Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. e1786, doi. 10.1002/onco.13887
- By:
- Publication type:
- Article
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 797, doi. 10.1002/onco.13819
- By:
- Publication type:
- Article
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 5, p. 433, doi. 10.1002/onco.13752
- By:
- Publication type:
- Article
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 463, doi. 10.1016/j.clml.2023.03.012
- By:
- Publication type:
- Article
TSCOT Thymic Epithelial Cell-Mediated Sensitive CD4 Tolerance by Direct Presentation.
- Published in:
- PLoS Biology, 2008, v. 6, n. 8, p. e191, doi. 10.1371/journal.pbio.0060191
- By:
- Publication type:
- Article
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions.
- Published in:
- Clinical Trials, 2019, v. 16, n. 3, p. 322, doi. 10.1177/1740774519836991
- By:
- Publication type:
- Article
Cross-priming utilizes antigen not available to the direct presentation pathway.
- Published in:
- Immunology, 2006, v. 119, n. 1, p. 63, doi. 10.1111/j.1365-2567.2006.02406.x
- By:
- Publication type:
- Article
US Food and Drug Administration regulatory updates in neuro-oncology.
- Published in:
- Journal of Neuro-Oncology, 2021, v. 153, n. 3, p. 375, doi. 10.1007/s11060-021-03789-5
- By:
- Publication type:
- Article
Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer.
- Published in:
- BJU International, 2021, v. 127, n. 4, p. 435, doi. 10.1111/bju.15227
- By:
- Publication type:
- Article
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2016, v. 118, n. 4, p. 590, doi. 10.1111/bju.13412
- By:
- Publication type:
- Article
Impact of an evolving regulatory landscape on skin cancer drug development in the United States.
- Published in:
- Dermatology Online Journal, 2022, v. 28, n. 2, p. 1, doi. 10.5070/D328257391
- By:
- Publication type:
- Article
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Poor immunogenicity of a self/tumor antigen derives from peptide--MHC-I instability and is independent of tolerance.
- Published in:
- Journal of Clinical Investigation, 2004, v. 114, n. 4, p. 551, doi. 10.1172/JCI200421695
- By:
- Publication type:
- Article
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
- Published in:
- Current Oncology Reports, 2020, v. 22, n. 11, p. N.PAG, doi. 10.1007/s11912-020-00974-z
- By:
- Publication type:
- Article
Using a Benefit–Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 106, n. 1, p. 123, doi. 10.1002/cpt.1461
- By:
- Publication type:
- Article